ALDX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.1M
-29.3%
5.9M
+64.9%
3.5M
-46.8%
6.7M
-16.7%
8.0M
R&D
1.8M
-47.3%
3.5M
+44.6%
2.4M
-44.0%
4.3M
-20.8%
5.4M
SG&A
2.3M
-2.8%
2.4M
+108.0%
1.1M
-51.9%
2.4M
-8.0%
2.6M
Operating Income
-4136274
+29.3%
-5850507
-64.9%
-3546918
+46.8%
-6667883
+16.7%
-8001132
EBITDA
-3981562
+31.1%
-5779801
-66.1%
-3480319
+47.3%
-6602767
+16.8%
-7937449
Net Income
-3762964
+31.0%
-5450273
-57.9%
-3452619
+46.6%
-6461507
+16.0%
-7688341
EPS (Basic)
$-0.06
+33.3%
$-0.09
-50.0%
$-0.06
+45.5%
$-0.11
+15.4%
$-0.13
EPS (Diluted)
$-0.06
+33.3%
$-0.09
-50.0%
$-0.06
+45.5%
$-0.11
+15.4%
$-0.13
Shares (Diluted)
60.4M
+0.1%
60.3M
+0.0%
60.3M
+0.3%
60.2M
+0.1%
60.1M
Aldeyra Therapeutics (ALDX) — Financials